Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Blood and Lymphatic Cancer Targets and TherapyOpen Access

Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

LGLiangquan GengUniversity of Science and Technology of ChinaECErling ChenUniversity of Science and Technology of ChinaYJYanping JiJiangsu University

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows early allo-HSCT improves overall survival in higher-risk MDS, suggesting UCBT as a viable alternative.

Key Points

  • Early allo-HSCT significantly improved overall survival at 3 years, achieving 70% compared to 50% for later transplants.
  • Transplant-related mortality was lower in the early HSCT group at 22.7% versus 46.5%, indicating better outcomes for timely interventions.
  • The study involved 70 higher-risk MDS patients stratified by diagnosis-to-transplant interval and pre-transplant treatments affecting outcomes.
  • UCBT offered a lower rate of chronic graft-versus-host disease, supporting its use when sibling donors are not available.

Cite This Study

Geng et al. (2025) studied this question.

synapsesocial.com/papers/68c1a5ff54b1d3bfb60e0105https://doi.org/10.2147/blctt.s527790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel2017 · 376 citations
  2. 2IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation2016 · 96 citations
  3. 3Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome2020 · 28 citations
  4. 4Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome2021 · 139 citations
  5. 5Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study2023 · 64 citations